Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Teva Second Quarter Profit Climbs 53 Percent

By Pharmaceutical Processing | July 27, 2010

NEW YORK (AP) — Teva Pharmaceutical Industries said its second-quarter net income leapt 53 percent as the biggest generic drug company in the world launched a pair of new products.

Teva is based in Israel, but most of its revenue comes from North America. The company said North American sales grew 17 percent to $2.48 billion in the latest quarter, with results boosted by new generic versions of the blood pressure drugs Hyzaar and Cozaar, and the birth control pill Yaz.

Net income for Teva rose to $797 million, or 88 cents per share, from $521 million, or 58 cents per share.

In March, Teva agreed to buy German drugmaker Ratiopharm GmbH for $5 billion in a deal intended to boost its sales in Europe.

Excluding one-time charges like amortization costs and expenses from the Ratiopharm deal, the company earned $1.08 per share. Revenue increased 12 percent, to $3.8 billion from $3.4 billion.

That tops Wall Street’s profit expectations by 4 cents, according to a poll by Thomson Reuters.

Teva also makes brand name drugs including the multiple sclerosis treatment Copaxone. Sales of Copaxone rose 13 percent to $773 million. Sales from its Parkinson’s disease drug Azilect grew 29 percent to $70 million.

The company reported strong sales of generics of the child asthma medication Pulmicort Respules, the Parkinson’s disease drug Mirapex, and the cancer drug Eloxatin.

U.S. sales rose 14 percent to $1.5 billion, Teva said. European sales grew 4 percent to $811 million, boosted by stronger generic sales in Italy, Spain, and France, and rising revenue from Copaxone and Azilect. Other international sales edged up 1 percent to $522 million.

Shares of Teva Pharmaceutical Industries Ltd. rose $1.68 to $51.83 in premarket trading.

 

Related Articles Read More >

Driving success in fast-paced high-tech pharma construction projects
This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE